ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Publisher： John Wiley & Sons Inc

E-ISSN： 1757-4684|7|6|831-847

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.7, Iss.6, 2015-06, pp. : 831-847

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922

By  

Molecular Carcinogenesis, Vol. 57, Iss. 2, 2018-02 ,pp. : 284-294

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase‐1 and ‐2

By  

Molecular Carcinogenesis, Vol. 899-1987, Iss. 10, 2015-10 ,pp. : 1214-1219

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase‐1 and ‐2

By  

Molecular Carcinogenesis, Vol. 54, Iss. 10, 2015-10 ,pp. : 1214-1219

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epigenetic induction of tissue inhibitor of matrix metalloproteinase‐3 by green tea polyphenols in breast cancer cells

By  

Molecular Carcinogenesis, Vol. 54, Iss. 6, 2015-06 ,pp. : 485-499

John Wiley & Sons Inc

Access to resources Recommend Favorite

Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance

By  

EMBO Molecular Medicine, Vol. 7, Iss. 11, 2015-11 ,pp. : 1385-1387

John Wiley & Sons Inc

Access to resources Recommend Favorite